Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 5/20 | 0.35 |
| ▸ | JAK1 | P23458 | 4/20 | 0.35 |
| ▸ | JAK3 | P52333 | 4/20 | 0.35 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 3/20 | 0.33 |
| ▸ | GRK5 | P34947 | 2/20 | 0.33 |
| ▸ | IGF1R | P08069 | 2/20 | 0.33 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9918521 | 0.84 | IGF1R (0.34) | LRRK2JAK2JAK1JAK3GRK5 | |
| SCHEMBL9918526 | 0.83 | LRRK2 (0.43) | LRRK2PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9918529 | 0.78 | JAK1 (0.34) | JAK2JAK1JAK3SYKTYK2 | |
| SCHEMBL9918544 | 0.77 | SMN1; SMN2 (0.44) | LRRK2NUDT1SYKALDH1A1 | |
| SCHEMBL9918519 | 0.75 | IGF1R (0.33) | LRRK2JAK2JAK1JAK3SYK | |
| SCHEMBL9918528 | 0.75 | SYK (0.32) | JAK2JAK1JAK3SYKIGF1R | |
| SCHEMBL9918523 | 0.71 | MAPT (0.41) | — | |
| SCHEMBL9918522 | 0.71 | CSF1R (0.38) | — | |
| SCHEMBL12832928 | 0.68 | LRRK2 (0.45) | LRRK2JAK2JAK1JAK3NUDT1 | |
| SCHEMBL12832699 | 0.68 | JAK2 (0.34) | JAK2JAK1JAK3SYKTYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | LRRK2 1567/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.